Devalingam Mahalingam, MD
Enriched profileAssociate Director for Clinical Research, Robert H. Lurie Comprehensive Cancer Center; Professor of Medicine, Hematology and Oncology Division, Northwestern University Feinberg School of Medicine · Northwestern University Feinberg School of Medicine
Devalingam Mahalingam is Associate Director for Clinical Research, Robert H. Lurie Comprehensive Cancer Center; Professor of Medicine, Hematology and Oncology Division, Northwestern University Feinberg School of Medicine at Northwestern University Feinberg School of Medicine. OpenAlex indexes 501 publications with 7,308 citations (h-index 47); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Devalingam Mahalingam, M.D., is Associate Director for Clinical Research, Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine. The public record shows 501 publications with 7,308 citations (h-index 47), centered on Pancreatic and Hepatic Oncology Research, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 10 companies, 1 NIH-funded awards (2022–2026).
- Top research focus: Pancreatic and Hepatic Oncology Research
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 10 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 15 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 98.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.northwestern.edu ↗
- Presenter
ASCO 2025 Annual Meeting, study on impact of erasglusib in metastatic pancreatic ductal adenocarcinoma
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.northwestern.edu ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
Sponsor: Northwestern University
- Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
Sponsor: Devalingam Mahalingam
Industry payments
Updated 18 Oct 2026
10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202511 payments$21,185openpaymentsdata.cms.gov ↗
- Exelixis Inc.Program year20259 payments
- Eli Lilly and CompanyProgram year20257 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
69.9%CD38-directed Cytolytic Antibody22.9%Daratumumab100%Part B, office-administered≥34 patientsOther monoclonal antibodies and antibody drug conjugates18.3%Teclistamab-cqyv100%Part B, office-administered≥12 patients+ 6 more classes in this area
Metabolism & gastrointestinal
12.4%Other antiemetics9.3%Fosaprepitant100%Part B, office-administered≥20 patientsSerotonin-3 Receptor Antagonist1.6%Palonosetron hcl79%Granisetron hydrochloride20%Ondansetron Odt2%Part D + Part B≥44 patients+ 1 more class in this area
Dermatology
8.3%Corticosteroid8.3%Methylprednisolone sodium succinate100%Part B, office-administered≥35 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
Congress activity
Updated 18 Oct 2026
116 congress contributions (2009–2026) across AACR, ASCO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 5255: KRAS subtype may modify the poor immunotherapy response in pancreatic cancer: Evidence from early phase trials
AACR Annual Meeting
AACR2026Co-author - A phase Ib/II study of zanzalintinib (XL092) in second line and beyond for the treatment of advanced hepatocellular carcinoma.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Most-cited works
by citation count (OpenAlex)- 01The Landscape of Targeted Therapies in TNBCArticle450 citations2020
- 02Targeting HSP90 for cancer therapyArticle317 citations2009
- 03Combined autophagy and HDAC inhibitionArticle285 citations2014
- 04
- 05TRAIL receptor signalling and modulation: Are we on the right TRAIL?Article272 citations2008
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/devalingam-mahalingam-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on recordAwards & honors
honors on the public record- Board Certification
American Board of Internal Medicine - Internal Medicine
- Board Certification
American Board of Internal Medicine - Medical Oncology
Secondary affiliations
appointments beyond the home institution- Member
Translational Research in Malignancy (TRIM) program, Northwestern University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.northwestern.edu ↗ - Medical staff privileges
Northwestern Memorial Hospital
Media & interviews
press, podcasts and appearances- Featured in video content
Breakthroughs for Physicians (Northwestern Medicine), topic: impact of elraglusib
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →breakthroughsforphysicians.nm.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Clyde Yancy, MD
Northwestern University Feinberg School of Medicine
Martin Tallman, MD
Northwestern University Feinberg School of Medicine
Al Benson, MD
Northwestern University Feinberg School of Medicine
Sanjiv Shah, MD
Northwestern University Feinberg School of Medicine
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH